CORRECTING AND REPLACING -- Agile Therapeutics
20 avr. 2021 10h56 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report...
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
20 avr. 2021 09h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report first quarter 2021 financial results after...
Agile Therapeutics to Present at Upcoming March Investor Conferences
05 mars 2021 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will...
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
01 mars 2021 16h05 HE
|
Agile Therapeutics, Inc.
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available Achieved Gross Revenue Target In Fourth Quarter 2020, Reflecting Initial Stocking of Twirla®...
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021
19 févr. 2021 08h35 HE
|
Agile Therapeutics, Inc.
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
14 mars 2018 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Agile Therapeutics Reports Third Quarter 2017 Financial Results
06 nov. 2017 16h20 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
10 oct. 2017 18h38 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today hosted the Company’s first analyst day in New York City to showcase its...
Agile Therapeutics Announces Proposed Offering of Common Stock
02 août 2017 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
27 juin 2017 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...